Literature DB >> 11888347

Cytomegalovirus and the aging population.

V C Emery1.   

Abstract

Human cytomegalovirus (HCMV) has the largest genome of any virus known to infect man. The virus has evolved many strategies to manipulate the host immune systems and so can remain latent and evade important immune responses. The human host mounts a substantial immune response against the virus, with up to 1% of the virus-specific CD8+ T cells being directed against specific epitopes. Acquisition of HCMV occurs progressively from an early age, and in developed countries the overall seroprevalence is approximately 60%. In contrast, specific communities such as gay men, lower socioeconomic groups and people residing in developing countries have seroprevalence rates that can exceed 90%. It is a widely held belief that successful control of viral infections decreases with increasing age because of a reduction in the capacity of the immune system. Studies in aging populations have shown a specific expansion of the CD8+, CD28- and CD57+ subset of cells in patients who are HCMV-seropositive. Prior infection with HCMV has also been associated with a significantly increased number of CD4+ and CD8+ lymphocytes, as well as cells expressing CD56 and HLA-DR. Thus, HCMV infection can cause substantial perturbations in T cell subsets and these effects persist in the aging population. In the context of solid organ transplantation, older age of both recipients and donors may serve to increase the frequency of donor-positive recipient-positive (D+R+) transplants, which have only a moderate risk of HCMV disease. In the context of HIV infection, age has been a dominant risk factor for progression to AIDS and death. At present, it does not appear that this can be explained by lack of immune control of HCMV in the aging population, although studies have identified prior HCMV infection as a risk factor for AIDS and death independent of age. We await further investigations to determine whether the immune control of HCMV in the elderly patient is as effective as in the younger adult, and whether this is linked to pathological consequences.

Entities:  

Mesh:

Year:  2001        PMID: 11888347     DOI: 10.2165/00002512-200118120-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  32 in total

1.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

Review 2.  Human cytomegalovirus glycoproteins.

Authors:  W J Britt; M Mach
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

3.  An association between cytomegalovirus infection and chronic rejection after liver transplantation.

Authors:  P C Evans; A Soin; T G Wreghitt; C J Taylor; D G Wight; G J Alexander
Journal:  Transplantation       Date:  2000-01-15       Impact factor: 4.939

Review 4.  Restoration of the immune system with anti-retroviral therapy.

Authors:  B Autran; G Carcelaint; T S Li; G Gorochov; C Blanc; M Renaud; M Durali; D Mathez; V Calvez; J Leibowitch; C Katlama; P Debré
Journal:  Immunol Lett       Date:  1999-03       Impact factor: 3.685

5.  More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts.

Authors:  A N Phillips; C A Lee; J Elford; A Webster; G Janossy; A Timms; M Bofill; P B Kernoff
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

6.  Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy.

Authors:  J R Deayton; P Wilson; C A Sabin; C C Davey; M A Johnson; V C Emery; P D Griffiths
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

7.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

Authors:  D Lowance; H H Neumayer; C M Legendre; J P Squifflet; J Kovarik; P J Brennan; D Norman; R Mendez; M R Keating; G L Coggon; A Crisp; I C Lee
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

8.  Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants.

Authors:  M Engstrand; C Tournay; M A Peyrat; B M Eriksson; J Wadström; B Z Wirgart; F Romagné; M Bonneville; T H Tötterman; O Korsgren
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

9.  Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.

Authors:  S B Boppana; W J Britt
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

10.  Congenital and maternal cytomegalovirus infections in a London population.

Authors:  P D Griffiths; C Baboonian; D Rutter; C Peckham
Journal:  Br J Obstet Gynaecol       Date:  1991-02
View more
  3 in total

1.  Cytomegalovirus ileitis in an immunocompetent elderly adult.

Authors:  Kum Hei Ryu; Sun Young Yi
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

2.  HCMV IL-10 suppresses cytokine expression in monocytes through inhibition of nuclear factor-kappaB.

Authors:  James Nachtwey; Juliet V Spencer
Journal:  Viral Immunol       Date:  2008-12       Impact factor: 2.257

3.  Cytomegalovirus Colitis Mimicking Rectal Carcinoma in a Young Immunocompetent Patient.

Authors:  Rushikesh Shah; Gaurang Vaidya; Aditya Kalakonda; Divey Manocha; Sekou Rawlins
Journal:  ACG Case Rep J       Date:  2015-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.